Drug Type DNA vaccine, Therapeutic vaccine |
Synonyms PUMVC3 DNA vaccine(University of Washington Bothell), WOKVAC, AST-302 |
Target |
Mechanism HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), IGF-1R antagonists(Insulin-like growth factor I receptor antagonists), IGFBP2 inhibitors(Insulin-like growth factor binding protein IIinhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization Aston SCIStartup |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Breast Cancer | Phase 2 | US | 30 Nov 2022 | |
Breast Cancer 3 | Phase 2 | US | 19 Feb 2018 | |
Residual Neoplasm | Phase 2 | US | 19 Feb 2018 | |
HER2 Positive Breast Cancer | Phase 2 | US | 19 Feb 2018 | |
HER2-negative breast cancer | Phase 1 | US | 02 Sep 2016 |
Phase 1 | 32 | WOKVAC+Sargramostim (Treatment (WOKVAC With Sargramostim) - Dose 150 mcg + 100 mcg Sargramostim) | fzhqrusquv(znxcfscsmc) = fbzotqfocj djthtcmkag (uwlwxmlqwc, qaiyrxraxc - fplsfcnwzy) View more | - | 19 Sep 2024 | ||
WOKVAC+Sargramostim (Treatment (WOKVAC With Sargramostim) - Dose 300 mcg + 100 mcg Sargramostim) | fzhqrusquv(znxcfscsmc) = iwvrrewppz djthtcmkag (uwlwxmlqwc, imgfjyarvy - hmuhvgybye) View more |